Drugs / HLX26
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05400265 | Jul 2022 → Aug 2023 | — | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT05078593 | Oct 2021 → Aug 2023 | cancer, lymphoma | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05787613 | Jul 2023 → Feb 2026 overdue | non-small cell lung carcinoma | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05584137 | Jun → Dec 2023 | colorectal carcinoma | Shanghai Henlius Biotech | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05787613 ↗ |
| Action | Inhibit | “it can block LAG-3 and its ligand interaction” PMID 41538111 ↗ Jan 2026 |
| Modality | Monoclonal antibody | “BACKGROUND: HLX26 is a novel, recombinant humanized anti-LAG-3 IgG4 monoclonal antibody” PMID 41538111 ↗ Jan 2026 |
| Route | Intravenous | “the patients will be given different doses(60mg, 150mg, 300mg, 500mg, 800mg Q3W) of HLX26 intravenously” NCT05078593 ↗ |
| Target | LAG3 | “HLX26 is a novel, recombinant humanized anti-LAG-3 IgG4 monoclonal antibody that exhibits high affinity for LAG-3” PMID 41538111 ↗ Jan 2026 |